These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30416686)

  • 61.
    Manem VS; Dhawan A
    Br J Radiol; 2019 Nov; 92(1103):20190198. PubMed ID: 31538514
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunohistochemical validation of COL3A1, GPR158 and PITHD1 as prognostic biomarkers in early-stage ovarian carcinomas.
    Engqvist H; Parris TZ; Kovács A; Nemes S; Werner Rönnerman E; De Lara S; Biermann J; Sundfeldt K; Karlsson P; Helou K
    BMC Cancer; 2019 Sep; 19(1):928. PubMed ID: 31533654
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.
    Mori S; Gotoh O; Kiyotani K; Low SK
    J Hum Genet; 2021 Sep; 66(9):853-868. PubMed ID: 34092788
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular insights into the classification of high-grade endometrial carcinoma.
    Hussein YR; Soslow RA
    Pathology; 2018 Feb; 50(2):151-161. PubMed ID: 29246451
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival.
    Engqvist H; Parris TZ; Rönnerman EW; Söderberg EMV; Biermann J; Mateoiu C; Sundfeldt K; Kovács A; Karlsson P; Helou K
    Oncotarget; 2018 Oct; 9(80):35162-35180. PubMed ID: 30416686
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Trefoil factor family proteins as potential diagnostic markers for mucinous invasive ovarian carcinoma.
    Werner Rönnerman E; Pettersson D; Nemes S; Dahm-Kähler P; Kovács A; Karlsson P; Parris TZ; Helou K
    Front Oncol; 2022; 12():1112152. PubMed ID: 36818673
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry.
    Engqvist H; Parris TZ; Kovács A; Rönnerman EW; Sundfeldt K; Karlsson P; Helou K
    Front Oncol; 2020; 10():162. PubMed ID: 32133296
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
    Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
    Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Genome-wide multi-omics profiling of the 8p11-p12 amplicon in breast carcinoma.
    Parris TZ; Rönnerman EW; Engqvist H; Biermann J; Truvé K; Nemes S; Forssell-Aronsson E; Solinas G; Kovács A; Karlsson P; Helou K
    Oncotarget; 2018 May; 9(35):24140-24154. PubMed ID: 29844878
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Mutational heterogeneity in non-serous ovarian cancers.
    Teer JK; Yoder S; Gjyshi A; Nicosia SV; Zhang C; Monteiro ANA
    Sci Rep; 2017 Aug; 7(1):9728. PubMed ID: 28852190
    [TBL] [Abstract][Full Text] [Related]  

  • 73. MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK.
    Liu P; Qi X; Bian C; Yang F; Lin X; Zhou S; Xie C; Zhao X; Yi T
    Oncol Lett; 2017 Jun; 13(6):4039-4046. PubMed ID: 28588697
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Multi-omics approaches to disease.
    Hasin Y; Seldin M; Lusis A
    Genome Biol; 2017 May; 18(1):83. PubMed ID: 28476144
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.
    Wang YK; Bashashati A; Anglesio MS; Cochrane DR; Grewal DS; Ha G; McPherson A; Horlings HM; Senz J; Prentice LM; Karnezis AN; Lai D; Aniba MR; Zhang AW; Shumansky K; Siu C; Wan A; McConechy MK; Li-Chang H; Tone A; Provencher D; de Ladurantaye M; Fleury H; Okamoto A; Yanagida S; Yanaihara N; Saito M; Mungall AJ; Moore R; Marra MA; Gilks CB; Mes-Masson AM; McAlpine JN; Aparicio S; Huntsman DG; Shah SP
    Nat Genet; 2017 Jun; 49(6):856-865. PubMed ID: 28436987
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes.
    Earp MA; Raghavan R; Li Q; Dai J; Winham SJ; Cunningham JM; Natanzon Y; Kalli KR; Hou X; Weroha SJ; Haluska P; Lawrenson K; Gayther SA; Wang C; Goode EL; Fridley BL
    Oncotarget; 2017 Jul; 8(29):46891-46899. PubMed ID: 28423358
    [TBL] [Abstract][Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.